Allchem Lifescience IPO Date, Review, Price and Key Information

Allchem Lifescience Limited IPO is fully book build issue and it includes fresh issue and offer for sale. The share offering contains a fresh issue worth ₹190 crores and offer for sale upto 0.72 crore shares.

The dates for the Allchem Lifescience Limited IPO have not been announced yet. The allotment process is expected to be finalized by [.].

The Allchem Lifescience Limited IPO is scheduled to list on BSE, NSE, with a listing date of [.]. The price band for the Allchem Lifescience Limited IPO has not been announced yet.

Registrar for this IPO is Mufg Intime India Private Limited and lead managers for Allchem Lifescience Limited IPO are Emkay Global Financial Services Limited.

IPO Schedule

IPO Open Date	-
IPO Close Date	-
IPO Allotment Date	-
Refund Initiation	-
Share credit in Demat	-
Listing Date	-

Key Details

Price Band	TBA
Lot Size	TBA
Face Value	₹10 Per Equity Share
Total Issue Size	7,155,000 Shares + ₹190 Crores
Fresh Issue	₹190.00 Crores
OFS Issue	7,155,000 Shares
Issue Type	Fresh Issue and Offer for Sale
Listing At	BSE, NSE

Share Reservation

Investor Category	Shares Offered
QIB	50%
Retail	35%
NII/HNI	15%

About Allchem Lifescience Limited Company

Overview: Catapharma Group, formed in 1986, is a prominent Indian chemical company specializing in manufacturing and supplying fine chemicals and pharmaceutical intermediates. Chandak Laboratories and SPC Lifesciences are also key players in the API intermediates and speciality chemicals. These companies serve both domestic and international markets.

Product Portfolio: These companies produce intermediates for APIs across various therapeutic segments, including CNS drugs (anxiolytics, antipsychotics, neurology), anti-infective drugs, endocrine drugs (antidiabetic), and oncology. Key products include piperazine derivatives, serving APIs like Flunarizine, Norfloxacin, Sitagliptin, and others.

Financial Performance: Catapharma Chemicals posted net sales of ₹109.2 Crore in FY24 with an impressive operating margin of 40.00%. Chandak Laboratories reported net sales of ₹239.75 Crore in FY23, showcasing strong growth. SPC Life Sciences reported net sales of ₹155.3 Crore in FY24, with an EBITDA margin that declined in the last year. While industry EBITDA margins fluctuate, Allchem Lifesciences shows consistent improvement attributed to efficiency and cost management.

Allchem Lifescience Limited Financial Details

Period Ended	30 Sep 2024	31 Mar 2024	31 Mar 2023	31 Mar 2022
Assets	246.30	224.65	186.68	124.02
Revenue	78.45	137.42	105.72	108.10
Profit After Tax	10.89	23.41	17.99	14.14
Net Worth	90.74	79.89	56.49	38.58
Reserves and Surplus	86.49	75.64	52.24	35.08
Total Borrowing	106.89	104.97	97.17	49.53

₹ In Crore

Key Performance Indicator

Basic EPS (in ₹)	Return on Net Worth (RoNW)	Net Asset Value (NAV)	Debt-Equity Ratio	Return on Equity (ROE)	Return on Capital Employed (ROCE)
3.06	34.33%	₹ 10.44

Offer Objectives

The Offer consists of a Fresh Issue and an Offer for Sale (OFS) by Promoter Selling Shareholders. The OFS involves up to 7,155,000 Equity Shares, potentially aggregating up to ₹[●] crore, with proceeds going to the selling shareholders. The company will not receive any proceeds from the Offer for Sale.

The Fresh Issue involves up to [●] Equity Shares aggregating up to ₹190 crore. Net proceeds from the Fresh Issue, after deducting offer-related expenses, are estimated to be ₹[●] crore. These net proceeds will be utilized towards the following:

Repayment and/or pre-payment of certain borrowings availed by the Company: ₹130 crore.
General corporate purposes: The remaining amount [●] crore.

The company also expects to benefit from the listing of Equity Shares, enhancing visibility, brand image, and creating a public market for its shares in India.

Promoters' contribution will be locked in as per SEBI regulations. 20% of the fully diluted post-Offer Equity Share capital held by promoters will be locked in for 18 months, and the excess shareholding will be locked in for 6 months from the date of allotment. Additionally, the entire pre-Offer Equity Share capital held by persons other than the Promoters will be locked in for a period of 6 months from the date of Allotment in the Offer.